MDXH MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissu…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch... | ||
 MDxHealth (MDXH) Q2 2026 Earnings Call Transcript Revenue grew 16% YoY to $27.2 million as net losses widened from integration costs. | ||
 MDxHealth S.A. Q2 2026 Earnings Call Summary Moby summary of MDxHealth S.A.'s Q2 2026 earnings call | ||
MDxHealth SA (MDXH) (Q2 2026) Earnings Call Highlights: Record Sequential Growth and Strategic ... MDxHealth SA (MDXH) delivers its largest quarter-over-quarter revenue acceleration in company history while eliminating a $10.4 million liability and strengthening its balance sheet. | ||
 MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates MDxHealth SA (MDXH) delivered earnings and revenue surprises of -50.00% and +5.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates 10x Genomics (TXG) delivered earnings and revenue surprises of +39.13% and +2.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||